about
Plasmablastic Lymphoma: A Review of Current Knowledge and Future DirectionsComparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base.Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohortCurrent knowledge on HIV-associated Plasmablastic Lymphoma.HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscapeChanges in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaCHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.The role of the tumor microenvironment in HIV-associated lymphomasSafety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies.Acute kidney injury and inflammatory immune reconstitution syndrome in mixed genotype (A/E) hepatitis B virus co-infection in HIV-associated lymphomaThe role of viral co-infection in HIV-associated non-AIDS-related cancersThe microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategiesViral co-infections and paraproteins in HIV: effect on development of hematological malignancies.Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.Association of early HIV viremia with mortality after HIV-associated lymphoma.Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice.Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases.Moving forward in HIV-associated cancer.Diagnosis and management of lymphomas and other cancers in HIV-infected patients.Therapy of HIV-associated lymphoma-recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ), in cooperation with the German AIDS Society (DAIG).Current status of treatment for primary effusion lymphoma.Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?Diffuse large B-cell lymphoma mimicking an ovarian tumor in a patient with HIV.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Multi-targeted therapy of everolimus in Kaposi's sarcoma associated herpes virus infected primary effusion lymphoma.Long-term survival in AIDS-related primary central nervous system lymphoma.Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trialHigh Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.Durable survival after chemotherapy in a HIV patient with Burkitt's lymphoma presenting with massive upper gastrointestinal bleeding.Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim AdministrationDose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).An Indian Perspective on HIV-associated Lymphomas.Advancing therapeutics in human immunodeficiency virus-associated lymphoma: where to go from here?HIV-1 Tat protein induces DNA damage in human peripheral blood B-lymphocytes via mitochondrial ROS production.Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.Incidence and risk factors for relapses in HIV-associated non-Hodgkin-lymphoma as observed in the German HIV-related lymphoma cohort study.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
P2860
Q26781831-EAD5F543-0CFB-4214-B99A-6EAB5299F67DQ30455450-404BA2AA-1AD0-4309-B6C9-69AE6D7252B9Q31110269-D41BEA5E-DBB2-487B-A2BA-2BB3C030D452Q33917964-78A6A55E-0B56-4E7B-8602-D2D632C96D72Q34531971-AC11B8CE-31BD-47BC-B6D1-73A43EE9A453Q34671009-48FA598E-C328-465C-B333-9853C095BC1EQ35511780-56E55444-39D9-4D7D-AFBD-BB5C3657F281Q35942794-51C37C23-6B8C-40B3-BF10-E959980B38DCQ35945221-8B745D10-5371-4861-B260-CAEBF89AF30CQ36515278-F54F7209-7513-48AC-A185-955C87B6C269Q36584311-B788BD6D-2353-47E5-AFDE-225B984CA40FQ36960884-A096840A-8191-44D5-BC5C-7980782CD47DQ37026769-234372AA-1B1A-4F39-9A42-C1C26899BF4FQ37094777-5F370108-3338-49B6-AC96-7D6B7F4E4105Q37106782-61B99843-D4B9-4659-A75F-6C0519A53161Q37171460-E41E8F48-0A62-40AD-BFC5-E8EDDA6E9806Q37291598-BBE8D55E-52B5-4F3B-8629-555B6D18F992Q37469500-702B7D38-C900-4BD1-87A3-6C47D258E0F4Q37624009-2F8D4D27-265A-4E59-A061-AE21C45AA8A4Q37627688-14D7C98A-448A-4279-BF45-EC30EAE96E1EQ38194845-B2BD0A54-8A31-4C22-82B0-0F8466BC8E22Q38210131-D2A6D0B5-C3D2-449C-BFE3-F3867D4B1BA6Q38264454-8BC60BFB-D637-4C9B-926A-5DCBF471CAE2Q38441989-38197D64-BFD2-40E2-8E2A-AEB157CBFB8CQ38459279-468E83AD-57FD-48DF-93C3-A07FBC0BCE00Q38996724-E60BBC45-2AA4-40E9-8BD4-C3D1DD3747CFQ40144368-EDF5AF25-367D-42C6-91A1-95A207700565Q40557791-D8CD7E0A-0302-42BC-9739-2A88D494ECDDQ40702849-B060DD38-A321-4A13-8DF4-F8FA5BF7E615Q41082604-37964590-34D6-44F6-B892-F3B0BEFBC939Q41103549-A3504F07-F8DC-4833-BD55-18BDF4D8B37EQ41104478-BDD139EF-43ED-42C5-96DD-8C10E25D62C8Q42277126-B3B5EA38-32F6-40A3-A167-8401A5B725C6Q42579494-ECF7B211-10E9-42F1-BB65-9BC527943EADQ45355467-9ADAF30D-CCFC-48EF-A5A4-BD8EF794C248Q46245165-3B792F3B-179E-4961-9ED6-055CA02DB0B4Q47436144-C848A1E0-52C0-45E2-AE14-374DF105B1E9Q47563526-44A8D89C-CB6C-4A27-970F-D3F4FA31CFA7Q50035090-E39DB768-360A-4FC2-924F-F11A6061CA9FQ51804722-39D0DEBA-BBB6-4FB5-88CA-0EFAD0B6C6CD
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
How I treat HIV-associated lymphoma
@ast
How I treat HIV-associated lymphoma
@en
How I treat HIV-associated lymphoma
@nl
type
label
How I treat HIV-associated lymphoma
@ast
How I treat HIV-associated lymphoma
@en
How I treat HIV-associated lymphoma
@nl
prefLabel
How I treat HIV-associated lymphoma
@ast
How I treat HIV-associated lymphoma
@en
How I treat HIV-associated lymphoma
@nl
P2860
P1433
P1476
How I treat HIV-associated lymphoma
@en
P2093
K. Dunleavy
W. H. Wilson
P2860
P304
P356
10.1182/BLOOD-2011-08-373738
P407
P577
2012-04-05T00:00:00Z